A Phase 1 Study to Assess the Effect of Itraconazole on ABBV-722 in Healthy Adult Participants

Study Identifier
M25-294
CT.gov Identifier
NCT07599761
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Recruiting
Sign up for trial alerts

Study Details

Medical Condition
  • Healthy Volunteer
    • Study Drug
  • ABBV-722
  • Itraconazole
    • Phase
    Phase 1
    Sex
    Female & Male
    Age
    18 - 65 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Laboratory values meet the criteria specified in the protocol. * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead electrocardiogram (ECG).
    Exclusion Criteria:
    * History of any clinically significant illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study treatment. * Consumption of alcohol, grapefruit products, Seville oranges, starfruit products or quinine/tonic water within the 72-hour period prior to study treatment administration. * Use of tobacco- or nicotine-containing products within 3 months (90 days) prior to the first dose of study treatment. * Participant has prior exposure to ABBV-722 within 90 days prior to the first dose of study treatment.

    Protocol Summary

    The objective of this study is to assess the effect of repeated doses of itraconazole on the single dose pharmacokinetics (PK) of ABBV-722.

    Study Locations

    Location
    Status
    Location
    Acpru /Id# 282143
    Grayslake, Illinois, United States, 60030
    Status
    Recruiting